Comparing the use of short-acting and long-acting calcium channel blockers in an HMO

Richard E. Johnson, David J. Harrowe, Bentson McFarland, James L. Bavry

Research output: Contribution to journalArticle

Abstract

One of the questions surrounding the controversy over the risks of MI among hypertensives taking calcium channel blockers (CCBs) is the dosage form, and whether the short-acting form may be more likely than the long- acting to increase the risk of MI. This preliminary study compared HMO members receiving the two dosage forms by sociodemographic and clinical characteristics, and by utilization (hospital, office visits, emergency room, outside of HMO services) prior to and during CCB use. The sampling frame was members with one or more dispensings for a CCB 1990 through 1994. Incident users were those who received one or more CCB dispensings and no cardiovascular disease-related drugs the year prior to their first dispensing of a CCB. CCB users were those who had at least 90 days of continuous CCB use. Short-acting outnumbered long-acting users by eight to one. Few incident users of long-acting CCBs were found. Among incident users, diagnoses and comorbidities were similar. In general, short-acting users appeared to have less risk of exposure to heart-related medications, but similar risks of exposure to non-heart-related drugs and to utilization of the various services during the year prior to first use. The odds of being exposed to heart-related medications and non-heart related medications and use of services during periods of use of CCBs were similar in general, but where differences were observed, the odds of being exposed were less among short- acting users. Users of the two dosage forms in this setting prior to reports questioning the safety of short-acting CCBs were different quantitatively and qualitatively making a retrospective comparative study difficult, perhaps not possible, due to substantial selection bias among users. Further patient selection bias has also undoubtedly occurred subsequent to the reports. The final answer to the relative safety and effectiveness of the different dosage forms of calcium channel blockers is likely to have come from randomized clinical trials.

Original languageEnglish (US)
Pages (from-to)155-166
Number of pages12
JournalPharmacoepidemiology and Drug Safety
Volume7
Issue number3
DOIs
StatePublished - May 1998

Fingerprint

Health Maintenance Organizations
Calcium Channel Blockers
Dosage Forms
Selection Bias
Drug Utilization
Safety
Office Visits
Patient Selection
Hospital Emergency Service
Comorbidity
Cardiovascular Diseases
Randomized Controlled Trials
Retrospective Studies

Keywords

  • Calcium channel blockers
  • Dosage forms
  • HMO

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Comparing the use of short-acting and long-acting calcium channel blockers in an HMO. / Johnson, Richard E.; Harrowe, David J.; McFarland, Bentson; Bavry, James L.

In: Pharmacoepidemiology and Drug Safety, Vol. 7, No. 3, 05.1998, p. 155-166.

Research output: Contribution to journalArticle

Johnson, Richard E. ; Harrowe, David J. ; McFarland, Bentson ; Bavry, James L. / Comparing the use of short-acting and long-acting calcium channel blockers in an HMO. In: Pharmacoepidemiology and Drug Safety. 1998 ; Vol. 7, No. 3. pp. 155-166.
@article{51e0a6828801406cb3466b0f3e871412,
title = "Comparing the use of short-acting and long-acting calcium channel blockers in an HMO",
abstract = "One of the questions surrounding the controversy over the risks of MI among hypertensives taking calcium channel blockers (CCBs) is the dosage form, and whether the short-acting form may be more likely than the long- acting to increase the risk of MI. This preliminary study compared HMO members receiving the two dosage forms by sociodemographic and clinical characteristics, and by utilization (hospital, office visits, emergency room, outside of HMO services) prior to and during CCB use. The sampling frame was members with one or more dispensings for a CCB 1990 through 1994. Incident users were those who received one or more CCB dispensings and no cardiovascular disease-related drugs the year prior to their first dispensing of a CCB. CCB users were those who had at least 90 days of continuous CCB use. Short-acting outnumbered long-acting users by eight to one. Few incident users of long-acting CCBs were found. Among incident users, diagnoses and comorbidities were similar. In general, short-acting users appeared to have less risk of exposure to heart-related medications, but similar risks of exposure to non-heart-related drugs and to utilization of the various services during the year prior to first use. The odds of being exposed to heart-related medications and non-heart related medications and use of services during periods of use of CCBs were similar in general, but where differences were observed, the odds of being exposed were less among short- acting users. Users of the two dosage forms in this setting prior to reports questioning the safety of short-acting CCBs were different quantitatively and qualitatively making a retrospective comparative study difficult, perhaps not possible, due to substantial selection bias among users. Further patient selection bias has also undoubtedly occurred subsequent to the reports. The final answer to the relative safety and effectiveness of the different dosage forms of calcium channel blockers is likely to have come from randomized clinical trials.",
keywords = "Calcium channel blockers, Dosage forms, HMO",
author = "Johnson, {Richard E.} and Harrowe, {David J.} and Bentson McFarland and Bavry, {James L.}",
year = "1998",
month = "5",
doi = "10.1002/(SICI)1099-1557(199805/06)7:3<155::AID-PDS344>3.0.CO;2-1",
language = "English (US)",
volume = "7",
pages = "155--166",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Comparing the use of short-acting and long-acting calcium channel blockers in an HMO

AU - Johnson, Richard E.

AU - Harrowe, David J.

AU - McFarland, Bentson

AU - Bavry, James L.

PY - 1998/5

Y1 - 1998/5

N2 - One of the questions surrounding the controversy over the risks of MI among hypertensives taking calcium channel blockers (CCBs) is the dosage form, and whether the short-acting form may be more likely than the long- acting to increase the risk of MI. This preliminary study compared HMO members receiving the two dosage forms by sociodemographic and clinical characteristics, and by utilization (hospital, office visits, emergency room, outside of HMO services) prior to and during CCB use. The sampling frame was members with one or more dispensings for a CCB 1990 through 1994. Incident users were those who received one or more CCB dispensings and no cardiovascular disease-related drugs the year prior to their first dispensing of a CCB. CCB users were those who had at least 90 days of continuous CCB use. Short-acting outnumbered long-acting users by eight to one. Few incident users of long-acting CCBs were found. Among incident users, diagnoses and comorbidities were similar. In general, short-acting users appeared to have less risk of exposure to heart-related medications, but similar risks of exposure to non-heart-related drugs and to utilization of the various services during the year prior to first use. The odds of being exposed to heart-related medications and non-heart related medications and use of services during periods of use of CCBs were similar in general, but where differences were observed, the odds of being exposed were less among short- acting users. Users of the two dosage forms in this setting prior to reports questioning the safety of short-acting CCBs were different quantitatively and qualitatively making a retrospective comparative study difficult, perhaps not possible, due to substantial selection bias among users. Further patient selection bias has also undoubtedly occurred subsequent to the reports. The final answer to the relative safety and effectiveness of the different dosage forms of calcium channel blockers is likely to have come from randomized clinical trials.

AB - One of the questions surrounding the controversy over the risks of MI among hypertensives taking calcium channel blockers (CCBs) is the dosage form, and whether the short-acting form may be more likely than the long- acting to increase the risk of MI. This preliminary study compared HMO members receiving the two dosage forms by sociodemographic and clinical characteristics, and by utilization (hospital, office visits, emergency room, outside of HMO services) prior to and during CCB use. The sampling frame was members with one or more dispensings for a CCB 1990 through 1994. Incident users were those who received one or more CCB dispensings and no cardiovascular disease-related drugs the year prior to their first dispensing of a CCB. CCB users were those who had at least 90 days of continuous CCB use. Short-acting outnumbered long-acting users by eight to one. Few incident users of long-acting CCBs were found. Among incident users, diagnoses and comorbidities were similar. In general, short-acting users appeared to have less risk of exposure to heart-related medications, but similar risks of exposure to non-heart-related drugs and to utilization of the various services during the year prior to first use. The odds of being exposed to heart-related medications and non-heart related medications and use of services during periods of use of CCBs were similar in general, but where differences were observed, the odds of being exposed were less among short- acting users. Users of the two dosage forms in this setting prior to reports questioning the safety of short-acting CCBs were different quantitatively and qualitatively making a retrospective comparative study difficult, perhaps not possible, due to substantial selection bias among users. Further patient selection bias has also undoubtedly occurred subsequent to the reports. The final answer to the relative safety and effectiveness of the different dosage forms of calcium channel blockers is likely to have come from randomized clinical trials.

KW - Calcium channel blockers

KW - Dosage forms

KW - HMO

UR - http://www.scopus.com/inward/record.url?scp=0031813136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031813136&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1099-1557(199805/06)7:3<155::AID-PDS344>3.0.CO;2-1

DO - 10.1002/(SICI)1099-1557(199805/06)7:3<155::AID-PDS344>3.0.CO;2-1

M3 - Article

C2 - 15073993

AN - SCOPUS:0031813136

VL - 7

SP - 155

EP - 166

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 3

ER -